Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y, Tamaki N, Nakanishi H, Kurosaki M, Tanaka Y, Inada K, Ishido S, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Okamoto R, Izumi N. Hayakawa Y, et al. Among authors: kirino s. Intern Med. 2023 Apr 1;62(7):973-978. doi: 10.2169/internalmedicine.0212-22. Epub 2022 Sep 6. Intern Med. 2023. PMID: 36070941 Free PMC article.
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: kirino s. J Viral Hepat. 2019 Jul;26(7):893-899. doi: 10.1111/jvh.13103. Epub 2019 May 3. J Viral Hepat. 2019. PMID: 30974045
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Kaneko S, et al. Among authors: kirino s. J Gastroenterol Hepatol. 2019 Nov;34(11):2004-2010. doi: 10.1111/jgh.14686. Epub 2019 May 21. J Gastroenterol Hepatol. 2019. PMID: 31017689
Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease.
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: kirino s. Sci Rep. 2019 Jul 12;9(1):10109. doi: 10.1038/s41598-019-46172-1. Sci Rep. 2019. PMID: 31300805 Free PMC article.
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib.
Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Kaneko S, et al. Among authors: kirino s. Hepatol Res. 2020 Jan;50(1):137-143. doi: 10.1111/hepr.13416. Epub 2019 Sep 6. Hepatol Res. 2020. PMID: 31349377
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Wang W, et al. Among authors: kirino s. Cancers (Basel). 2019 Oct 9;11(10):1517. doi: 10.3390/cancers11101517. Cancers (Basel). 2019. PMID: 31601010 Free PMC article.
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Kirino S, et al. J Gastroenterol Hepatol. 2020 Sep;35(9):1595-1601. doi: 10.1111/jgh.14990. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31975419
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Takahashi Y, Izumi N. Tamaki N, et al. Among authors: kirino s. J Med Virol. 2020 Aug;92(8):1355-1358. doi: 10.1002/jmv.25692. Epub 2020 Feb 7. J Med Virol. 2020. PMID: 31994737
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Kirino S, et al. PLoS One. 2020 Apr 20;15(4):e0231828. doi: 10.1371/journal.pone.0231828. eCollection 2020. PLoS One. 2020. PMID: 32310967 Free PMC article.
Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor.
Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, Okada M, Shimizu T, Higuchi M, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Osawa L, et al. Among authors: kirino s. Int J Mol Sci. 2020 May 21;21(10):3640. doi: 10.3390/ijms21103640. Int J Mol Sci. 2020. PMID: 32455631 Free PMC article.
59 results